Bone Biology and Physiology

Buck, Donald W.; Dumanian, Gregory A.

doi:10.1097/prs.0b013e31824eca94

Cited by 83 publications

(66 citation statements)

References 22 publications

(88 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1). Cortical bone is highly dense and consists of a hierarchical structure, each with in a different size scale, 12 see Table I. These range from the solid material (> 3 mm), to the cylindrically organized osteons (10–500 μ m), lamellae (3–20 μ m), and the collagen-mineral composite (60–600 nm).…”

Section: Bone Propertiesmentioning

confidence: 99%

Scaffold Design for Bone Regeneration

Polo-Corrales¹,

Latorre-Esteves²,

Ramı́rez-Vick³

2014

j. nanosci. nanotech.

744

502

View full text Add to dashboard Cite

The use of bone grafts is the standard to treat skeletal fractures, or to replace and regenerate lost bone, as demonstrated by the large number of bone graft procedures performed worldwide. The most common of these is the autograft, however, its use can lead to complications such as pain, infection, scarring, blood loss, and donor-site morbidity. The alternative is allografts, but they lack the osteoactive capacity of autografts and carry the risk of carrying infectious agents or immune rejection. Other approaches, such as the bone graft substitutes, have focused on improving the efficacy of bone grafts or other scaffolds by incorporating bone progenitor cells and growth factors to stimulate cells. An ideal bone graft or scaffold should be made of biomaterials that imitate the structure and properties of natural bone ECM, include osteoprogenitor cells and provide all the necessary environmental cues found in natural bone. However, creating living tissue constructs that are structurally, functionally and mechanically comparable to the natural bone has been a challenge so far. This focus of this review is on the evolution of these scaffolds as bone graft substitutes in the process of recreating the bone tissue microenvironment, including biochemical and biophysical cues.

show abstract

Section: Bone Propertiesmentioning

confidence: 99%

Scaffold Design for Bone Regeneration

Polo-Corrales¹,

Latorre-Esteves²,

Ramı́rez-Vick³

2014

j. nanosci. nanotech.

744

502

View full text Add to dashboard Cite

show abstract

“…Complex osteoclastogenesis is governed by macrophage colony-stimulating factor 1 (M-CSF) and receptor activator of the NF-κB (RANK) ligand (RANKL), as well as other cytokines secreted by osteoblasts and osteocytes that control various steps of the osteoclast differentiation process, including precursor proliferation, commitment, differentiation, and maturation [49]. In osteoclast precursors, M-CSF can stimulate expression of RANK, which promotes osteoclast differentiation [50].…”

Section: Foxos Activate Osteoclastogenesismentioning

confidence: 99%

The Roles of FoxO Transcription Factors in Regulation of Bone Cells Function

Chen

et al. 2020

IJMS

View full text Add to dashboard Cite

Forkhead box class O family member proteins (FoxOs) are evolutionarily conserved transcription factors for their highly conserved DNA-binding domain. In mammalian species, all the four FoxO members, FoxO1, FoxO3, FoxO4, and FoxO6, are expressed in different organs. In bone, the first three members are extensively expressed and more studied. Bone development, remodeling, and homeostasis are all regulated by multiple cell lineages, including osteoprogenitor cells, chondrocytes, osteoblasts, osteocytes, osteoclast progenitors, osteoclasts, and the intercellular signaling among these bone cells. The disordered FoxOs function in these bone cells contribute to osteoarthritis, osteoporosis, or other bone diseases. Here, we review the current literature of FoxOs for their roles in bone cells, focusing on helping researchers to develop new therapeutic approaches and prevent or treat the related bone diseases.

show abstract

“…The coupling process from bone resorption to formation is important for bone homeostasis (18). Suppressing bone resorption and enhancing bone formation are favorable options for preventing osteoporosis.…”

Section: Discussionmentioning

confidence: 99%

Sanguinarine protects against ovariectomy-induced osteoporosis in mice

Chu

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

Natural compounds are alternative agents that have therapeutic potential for preventing and treating osteoporosis. Traditionally, sanguinarine has been used clinically due to its diverse biological properties, including antimicrobial, anti-inflammatory and anticancer effects. Recently, for the first time, it was reported that sanguinarine inhibits osteoclast differentiation and bone resorption by suppressing the tumor necrosis factor ligand superfamily member 11-induced nuclear factor-κB and extracellular signal-regulated kinase signaling pathways in vitro. Therefore, the present study further investigated the pharmacological effect of sanguinarine on osteoporosis in vivo. Micro-computed tomography and histomorphometry analysis demonstrated that sanguinarine, at low and high concentrations, prevents ovariectomy (OVX)-induced bone loss. In addition, further investigation of the cellular response in vivo revealed that sanguinarine inhibited osteoclastic bone resorption and promoted osteoblastic bone formation in a dose-dependent manner. Therefore, the present study demonstrated that sanguinarine protected mice from OVX-induced osteoporosis by modulating bone remodeling, indicating that sanguinarine may have potential in the treatment of osteoporosis.

show abstract

Bone Biology and Physiology

Cited by 83 publications

References 22 publications

Scaffold Design for Bone Regeneration

Scaffold Design for Bone Regeneration

The Roles of FoxO Transcription Factors in Regulation of Bone Cells Function

Sanguinarine protects against ovariectomy-induced osteoporosis in mice

Contact Info

Product

Resources

About